Table 5.
Candida strains | Supernatant aBBHN-CFS# |
|
---|---|---|
ADMa | BDMb | |
Reference strains | ||
Candida albicans ATCC 90028 | + | ++ |
Candida krusei ATCC 6258 | + | ++ |
Candida parapsilosis ATCC 22019 | + | ++ |
Clinical isolates from vaginal swabs | ||
Candida albicans 1-V | + | + |
Candida albicans 2-V | ++ | ++ |
Candida glabrata 1-V | + | + |
Candida krusei 1-V | + | ++ |
Clinical isolates from rectal swabs | ||
Candida albicans 1-R | + | + |
Candida albicans 2-R | + | + |
Candida glabrata 1-R | + | + |
Candida krusei 1-R | + | ++ |
Candida tropicalis 1-R | + | + |
Cell-free supernatant was obtained after 96 h of incubation from broth culture of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 grown in combination (aBBHN-CFS).
For the agar diffusion method (ADM) +++ (very strong): diameter of inhibition zone ≥20.0 mm; ++ (strong): diameter of inhibition zone (20.0, 15.0] mm; + (weak): diameter of inhibition zone (15.0, 10.0] mm; - (no activity): diameter of inhibition zone <10.0 mm; punch diameter = 8.0 mm.
For the broth dilution method (BDM) +++ (very strong): ≤12.5% v/v; ++ (strong): 25.0% v/v; + (weak): 50.0% v/v; - (no activity): >50.0% v/v.